Previous:
PFMD
From Testing to Targeted Treatments
2025 Annual Report
Brought to fruition with
What changed because the
FT3 community worked together?
In 2025, the FT3 community continued working toward a shared goal: helping ensure that patients who can benefit from precision medicine are able to access the right care at the right time.
Across countries and stakeholder groups, patient advocates, healthcare professionals, researchers, industry partners and policy leaders worked together to address practical barriers to implementation, from biomarker testing workflows and shared decision-making, to value assessment and patient-centered evidence.
This year, the FT3 community:
- Supported implementation and advocacy efforts in countries across healthcare contexts, including Canada, Brazil, Mexico, Nigeria and the Philippines
- tested educational and communication tools in real-world clinical settings
- strengthened collaboration across multidisciplinary care teams
- advanced dialogue on the societal and human-centered value of precision medicine
In Canada, FT3 partners engaged 116 patients across 5 disease areas through the ADAPT-CARE study, generating real-world insights on how educational resources can support provider-patient communication and informed treatment discussions.
In Nigeria, patients reported improved understanding of targeted therapies through locally adapted educational materials, while in the Philippines, healthcare professionals worked together to identify barriers affecting biomarker testing workflows and diagnostic turnout times.
The examples throughout this report reflect a growing global community focused on testing what works, learning from implementation, and helping accelerate change across health systems.
FT3’s Membership Growth
and growing collaborative network
A growing collaborative network Including patient organizations, healthcare professionals, professional societies, industry partners and global health leaders working together to accelerate access to precision medicine.
Associate Members
Special thanks to all the organizations that continued their unwavering support and contribution in 2023:
FT3 Outreach and
community growth
The FT3 community continues to grow in its ability to connect people, strengthen collaboration, and support real-world implementation of precision medicine across different healthcare contexts.
Today, the FT3 network brings together patient advocates, healthcare professionals, researchers, industry leaders and policy experts working collectively to accelerate patient access to precision medicine.
40+
Members
4,500+
Synapse users
200+
Initiatives mapped across the precision medicine ecosystem
3
Global forums advancing dialogue on value assessment and patient-centered evidence
6
Patient Experience Data methodologies captured to support HTA discussions
300+
Nurses engaged globally across 60+ countries and territories
200
Patients engaged through clinical pilots evaluating educational resources and shared decision-making
2
Global demonstration pilots launched to test scalable implementation models
Achievements
Click on the tabs above to navigate through sections
In 2025, the FT3 community continued contributing to international discussions on how health systems evaluate and integrate precision medicine.
Across engagements at ISPOR, HTAi and PEOF, FT3 members helped advance conversations on:
- Patient centered value assessment
- Patient experience data (PED)
- Shared decision-making
- Broader societal and human-centered value in HTA processes
2025 progress
- 6 PED methodologies collected
- 500+ downloads of the HTA Value Drivers Casebook
- 4 new advocacy tools added to the Access & Advocacy Roadmap
- 30+ stakeholder perspectives contributed to FT3’s collective response to the HEMA consultation
Together with more than 10 local and global partners, FT3 supported a multi-stakeholder prioritization exercise in Mexico focused on barriers to precision medicine access.
Impact
- 150+ stakeholders engaged
- 10 priority actions identified across system readiness dimensions
- Foundations laid for future policy and advocacy discussions around precision medicine implementation
The initiative demonstrated how local leadership, supported by global expertise and practical tools, can help accelerate policy conversations.
Francisco Freyria (FUTEJE), our local advocacy leader in Mexico, shared his excitement “to bring to patients the access that is needed into precision medicine”
Click on the tabs above to navigate through sections
Through the ADAPT-CARE study in Canada, FT3 partners explored how precision medicine educational materials could support provider–patient communication in clinical practice.
Impact
- 116 patients engaged across 5 disease areas
- 70% of patients reported increased awareness of targeted therapies
- 69% found the materials easy or very easy to understand
- 73% said being involved in treatment decisions was “very important”
The study also highlighted communication gaps around biomarker testing and treatment discussions.
"Knowing that my care can be personalized gives me
more confidence and helps me feel more in control of
my treatment journey."
— Patient participant
In partnership with Project Pink Blue, FT3 evaluated how locally adapted educational materials could support patient understanding of precision medicine concepts and targeted therapies.
Impact
- 70+ patients engaged in focus groups
- 2 publications informing broader policy and care discussions
- Patients reported the materials were useful and recommended they be shared earlier in the care journey
- Several patients shared they were receiving targeted therapies without fully understanding them beforehand
One patient reflected:
"I didn't understand it when my doctor recommended it. But after reading this material, I got to know it better."
For Runcie Chidebe, Executive Director of Project Pink Blue:
"FT3’s ability to bring together diverse voices and co-create solutions makes it a true convening force — that’s where the magic happens"
The initiative reinforced the importance of accessible, culturally relevant educational materials in supporting informed conversations between patients and healthcare professionals.
Through the FT3-GPON Community of Practice:
- 300+ nurses engaged globally
- across 60+ countries and territories
- through 3 global community meetings
The initiative created space for nurses from different healthcare contexts to share experiences, implementation challenges and practical insights from precision oncology care.
"Nurses in LMIC with overwhelming patient assignments
and responsibilities and without training in scholarly
writing are unable to share their practice realities
in the literature. Workshops like this FT3 and GPON
collaboration allow their voices to be heard and we
learn how we can be of service to support them and
hence their patients."
— Julia Challinor on the Nurse Community of
Practice Workshop
FT3 also continued testing the Biomarker Test Report Disclosure Tool designed to support communication between pathologists, oncologists and patients.
Progress in 2025
- Workshops conducted with 30+ clinicians in Argentina
- Shared with 200+ clinicians across LATAM
- Clinical testing planned in Italy with lung cancer patients
The initiative aims to support clearer communication around biomarker testing results and improve understanding across the care pathway.
Click on the tabs above to navigate through sections
A local collaboration supported by FT3 identified barriers affecting precision diagnostics and biomarker testing turnaround times in the Philippines.
Impact
- 21 barriers to precision diagnostics identified
- 261 healthcare professionals trained
- 5 medical institutions engaged
- 22 ambassadors supported to help advance institutional advocacy efforts
The initiative focused on improving tissue sampling and biopsy procedures through multidisciplinary training involving pulmonologists, radiologists, pathologists and oncologists.
"Being part of the FT3 community empowered me to
contribute solutions, not only as a biomarker advocate
but also as a bridge to pathologists’ perspectives.
What began as an ambitious idea has now grown into a
valuable initiative with momentum to shape future
capacity-building efforts across the country."
— Dr. Herdee Luna, Oncologist
Launching scalable demonstration pilots.
Two new demonstration pilots launched in 2025 to test scalable approaches to precision medicine implementation:
Precision in Practice
A multidisciplinary training initiative supporting healthcare professionals across 6 institutions and countries in improving biomarker testing workflows and collaboration across care teams.
Care Compass
An adaptable patient pathway navigator being developed to help healthcare professionals and patients access trusted information throughout the care journey.
These initiatives reflect FT3’s growing focus on identifying, testing and scaling practical approaches that can support implementation across different healthcare systems.
Our Financial Overview in 2025 (k€)
All 2025 financials are audited and confirmed for accuracy.
1,252
Turnover
1,242
Program Expenses
10
Net Result
How We Allocate Our Resources (k€)
60.2%
Testing and scaling practical approaches that help bring precision medicine into real-world care
26.8%
Building a robust and impactful organization including membership and business development, and managing FT3 governance structures
12.8%
Building awareness and conditions for better access including events and communication campaigns
0.2%
Other: audit, insurance, training
5.33
Average FTE
Team
